Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Successful treatment of ulcerative colitis associated with hypereosinophilic syndrome/chronic eosinophilic leukemia.

Awano N, Ryu T, Yoshimura N, Takazoe M, Kitamura S, Tanaka M.

Intern Med. 2011;50(16):1741-5. Epub 2011 Aug 15.

2.

Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.

Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A, Całbecka M, Gajkowska J, Seferyńska I, Hałasz M, Woszczyk D, Markiewicz M, Krzemień S.

Hematol Oncol. 2010 Jun;28(2):93-7. doi: 10.1002/hon.919.

PMID:
19728396
3.

FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.

Wang LN, Pan Q, Fu JF, Shi JY, Jin J, Li JM, Hu J, Zhao WL, Chen Z, Chen SJ.

Chin Med J (Engl). 2008 May 20;121(10):867-73.

PMID:
18706197
4.

Response to imatinib mesylate in patients with hypereosinophilic syndrome.

Arefi M, García JL, Briz MM, de Arriba F, Rodríguez JN, Martín-Núñez G, Martínez J, López J, Suárez JG, Moreno MJ, Merino MA, Gutiérrez NC, Hernández-Rivas JM.

Int J Hematol. 2012 Sep;96(3):320-6. doi: 10.1007/s12185-012-1141-7. Epub 2012 Jul 18.

PMID:
22806436
5.

PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.

Vigna E, Lucia E, Gentile M, Mazzone C, Bisconte MG, Gentile C, Armentano A, Ottaviani E, Rondoni M, Martinelli G, Morabito F.

Cancer Chemother Pharmacol. 2008 Apr;61(4):713-6. Epub 2007 Jun 5.

PMID:
17549478
6.

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.

Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J.

Br J Haematol. 2008 Apr;141(2):200-4. doi: 10.1111/j.1365-2141.2008.07033.x. Epub 2008 Feb 26.

PMID:
18307562
7.

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE.

Blood. 2004 Apr 15;103(8):2879-91. Epub 2003 Nov 20. Review.

8.

FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.

Cools J.

Verh K Acad Geneeskd Belg. 2005;67(3):169-76. Review.

PMID:
16089297
9.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.

Coutré S, Gotlib J.

Semin Cancer Biol. 2004 Feb;14(1):23-31. Review. Erratum in: Semin Cancer Biol. 2004 Aug;14(4):306. Corrected and republished in: Semin Cancer Biol. 2004 Aug;14(4):307-15.

PMID:
14757533
10.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.

Coutré S, Gotlib J.

Semin Cancer Biol. 2004 Aug;14(4):307-15. Review.

PMID:
15305431
11.

[The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].

Li B, Zhang GS, Dai CW, Pei MF.

Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):448-52. Chinese.

PMID:
15854548
12.

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.

Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NC, Hehlmann R, Hochhaus A, Reiter A.

Br J Haematol. 2008 Dec;143(5):707-15. doi: 10.1111/j.1365-2141.2008.07294.x. Epub 2008 Oct 17.

PMID:
18950453
13.

The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.

La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P, Martelli MF, Mecucci C.

Haematologica. 2005 May;90(5):596-601.

14.

Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia.

Tanaka H, Iwato K, Asou H, Kimura A.

Intern Med. 2010;49(12):1195-200. Epub 2010 Jun 15.

15.

Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.

Arai A, Yan W, Wakabayashi S, Hayashi S, Inazawa J, Miura O.

Int J Hematol. 2007 Oct;86(3):233-7. Review.

PMID:
17988989
16.

[Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].

Green L, Kahn JE, Dufour JF, Le Scanff J, Charhon A, Broussolle C, Sève P.

Rev Med Interne. 2010 Apr;31(4):305-8. doi: 10.1016/j.revmed.2009.08.005. Epub 2010 Feb 18. French.

PMID:
20167399
17.

A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.

Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, Simon HU.

Allergy. 2009 Jun;64(6):913-8. doi: 10.1111/j.1398-9995.2009.01943.x. Epub 2009 Feb 7.

18.

[Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].

Sekkach Y, Mekouar F, Jira M, Elqatni M, Elomri N, Fatihi J, Badaoui M, Hammi S, Smaali J, El Khattabi A, Amezyane T, Abouzahir A, Ghafir D.

Ann Pharm Fr. 2011 Sep;69(5):277-81. doi: 10.1016/j.pharma.2011.07.004. Epub 2011 Sep 8. French.

PMID:
21924129
19.

Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.

Stone RM, Gilliland DG, Klion AD.

Semin Oncol. 2004 Apr;31(2 Suppl 6):12-7. Review.

PMID:
15175999
Items per page

Supplemental Content

Write to the Help Desk